EVX B2
Alternative Names: EVX-B2Latest Information Update: 28 Oct 2024
Price :
$50 *
At a glance
- Originator Evaxion Biotech
- Developer Evaxion Biotech; UMass Chan Medical School
- Class Bacterial vaccines; Protein vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Gonorrhoea
- No development reported Cystic fibrosis-associated respiratory tract infections; Pseudomonal infections
Most Recent Events
- 28 Oct 2024 No recent reports of development identified for preclinical development in Cystic-fibrosis-associated-respiratory-tract-infections(Prevention) in Denmark
- 28 Oct 2024 No recent reports of development identified for preclinical development in Pseudomonal-infections(Prevention) in Denmark
- 06 Sep 2022 Early research in Gonorrhoea (Prevention) in Denmark ( (Evaxion Biotech pipeline, September 2022)